Back

Inflection in prevalence of SARS-CoV-2 infections missing the N501Y mutation as a marker of rapid Delta (B.1.617.2) lineage expansion in Ontario, Canada

Brown, K. A.; Gubbay, J.; Buchan, S. A.; Daneman, N.; Mishra, S.; Patel, S.; Day, T.

2021-06-25 infectious diseases
10.1101/2021.06.22.21259349
Show abstract

BackgroundThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta lineage (B.1.617.2) was implicated in the SARS-CoV-2 surge in India. We sought to describe the rapid expansion of the Delta lineage in Ontario, Canada (population 15 million) using mutation profile information and confirmatory whole genome sequencing. MethodsAll laboratory-confirmed SARS-CoV-2 cases reported to Public Health Ontario between April 1st and June 12th 2021, with cycle threshold values [≤]35, were eligible for screening for the N501Y and the E484K mutations. We classified cases via mutation screening as: (1) N501Y-/E484K- (wild-type/Delta), (2) Alpha (N501Y+/E484K-), (3) Beta/Gamma (N501Y+/E484K+), or (4) N501Y-/E484K+ (predominantly B.1.525, and B.1.1.318). ResultsThe N501Y-/E484K- mutation profile went from having a 29% transmission deficit relative to Alpha (relative Re = 0.71, 95%CI: 0.64, 0.77) on April 1st to having a 50% transmission advantage on June 12th (relative Re = 1.50, 95%CI: 1.31, 1.71). Whole genome sequencing of N501Y-/E484K-cases (N=583) confirmed that the pattern of increasing relative reproduction number coincided with the replacement of wild-type with Delta variant (from 2.2% in early April, to 83% in late May). DiscussionDelta is rapidly overtaking other SARS-CoV-2 variants in Ontario, and has a substantial transmission advantage. An inflection in the proportion of cases missing the N501Y mutation from rapidly decreasing to rapidly increasing,3 may be an early warning signal for Delta lineage expansion.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Canadian Medical Association Journal
based on 15 papers
Top 0.1%
11.0%
2
Emerging Infectious Diseases
based on 84 papers
Top 1%
6.3%
3
The Journal of Infectious Diseases
based on 137 papers
Top 1.0%
5.8%
4
CMAJ Open
based on 12 papers
Top 0.1%
5.3%
5
Clinical Infectious Diseases
based on 219 papers
Top 6%
4.7%
6
International Journal of Infectious Diseases
based on 115 papers
Top 2%
4.5%
7
eLife
based on 262 papers
Top 9%
2.8%
8
PLOS ONE
based on 1737 papers
Top 80%
2.8%
9
The Lancet Infectious Diseases
based on 57 papers
Top 2%
2.8%
10
BMC Infectious Diseases
based on 110 papers
Top 3%
2.8%
11
JAMA Network Open
based on 125 papers
Top 8%
2.3%
50% of probability mass above
12
Science
based on 46 papers
Top 3%
1.8%
13
The Lancet Microbe
based on 33 papers
Top 2%
1.6%
14
Open Forum Infectious Diseases
based on 124 papers
Top 6%
1.6%
15
Nature Microbiology
based on 21 papers
Top 0.2%
1.6%
16
Virus Evolution
based on 26 papers
Top 0.6%
1.6%
17
Nature
based on 58 papers
Top 5%
1.6%
18
Journal of Clinical Virology Plus
based on 10 papers
Top 0.1%
1.3%
19
Scientific Reports
based on 701 papers
Top 78%
1.3%
20
JMIR Public Health and Surveillance
based on 45 papers
Top 8%
1.3%
21
Annals of Internal Medicine
based on 27 papers
Top 1%
1.3%
22
Journal of Infection
based on 64 papers
Top 5%
1.3%
23
Nature Communications
based on 483 papers
Top 36%
1.2%
24
Journal of Clinical Virology
based on 54 papers
Top 3%
1.2%
25
BMJ Open
based on 553 papers
Top 47%
1.2%
26
Eurosurveillance
based on 77 papers
Top 8%
0.8%
27
JAMA
based on 17 papers
Top 1%
0.8%
28
Viruses
based on 79 papers
Top 6%
0.8%
29
The Lancet Regional Health - Americas
based on 20 papers
Top 1%
0.7%
30
Clinical Microbiology and Infection
based on 54 papers
Top 6%
0.7%